Johanna Valenzuela Oses

Ms. Johanna Valenzuela Oses

Pharmaceuticals sciences, Universidad Nacional de Córdoba, Córdoba, Argentina
orcid
phD student

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2015 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
JPJuliana de Almeida Pachioni-Vasconcelos
Juliana de Almeida Pachioni-Vasconcelos
André Moreni LopesAndré Moreni Lopes
André Moreni Lopes
AAAlexsandra Apolinário
Alexsandra Apolinário
Johanna Valenzuela OsesJohanna Valenzuela Oses
Johanna Valenzuela Oses
Juliana Souza Ribeiro CostaJuliana Souza Ribeiro Costa
Juliana Souza Ribeiro Costa
CRCARLOTA RANGEL-YAGUI
CARLOTA RANGEL-YAGUI
Nanostructured systems, such as nanoemulsions and polymersomes, are important tools to develop safe and effective therapeutic protein preparations.

1 December 2017 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
Johanna Valenzuela OsesJohanna Valenzuela Oses
Johanna Valenzuela Oses
Mónica C. GarcíaMónica C. García
Mónica C. García
VFValker Feitosa
Valker Feitosa
JPJuliana A. Pachioni-Vasconcelos
Juliana A. Pachioni-Vasconcelos
SFSandro Gomes Filho
Sandro Gomes Filho
CRCARLOTA RANGEL-YAGUI
CARLOTA RANGEL-YAGUI

13 February 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
JTJazmin Torres
Jazmin Torres
Johanna Valenzuela OsesJohanna Valenzuela Oses
Johanna Valenzuela Oses
Antonio M. Rabasco-AlvarezAntonio M. Rabasco-Alvarez
Antonio M. Rabasco-Alvarez
María Luisa González-RodríguezMaría Luisa González-Rodríguez
María Luisa González-Rodríguez
Mónica C. GarcíaMónica C. García
Mónica C. García
Recent advancements in nanotechnology have revolutionized cancer therapy—one of the most pressing global health challenges and a leading cause of death—through the development of liposomes (L), lipid-based nanovesicles known for their biocompatibility and ability to encapsulate both hydrophilic and lipophilic drugs. More recent innovations have led to the creation of stimuli-responsive L that release their payloads in response to specific endogenous or exogenous triggers. Dual- and multi-responsive L, which react to multiple stimuli, offer even greater precision, improving therapeutic outcomes while reducing systemic toxicity. Additionally, these smart L can adjust their physicochemical properties and morphology to enable site-specific targeting and controlled drug release, enhancing treatment efficacy while minimizing adverse effects. This review explores the latest advancements in endogenous stimuli-responsive liposomal nanocarriers, as well as dual- and multi-responsive L that integrate internal and external triggers, with a focus on their design strategies, mechanisms, and applications in cancer therapy.